Agios Pharmaceuticals (AGIO) announced that it had obtained positive results in a phase 3 study treating patients with bile duct cancer. Specifically, these are patients who have the IDH1 mutation. The company obtained these positive results using its drug Tibsovo. The thing is that Tibsovo already received its first approval last year by the FDA treating patients with acute myeloid leukemia (AML) who have the IDH1 mutation. Not only were positive results obtained, but it provides hope as a new treatment option for this specific bile duct cancer population. The main treatment option